Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma

Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma is a phase 2/3 interventional study registered as NCT02793583 by TG Therapeutics, Inc., with 710 participants recorded, started 2016-05-25 and due to reach its primary completion in 2022-05-31. Interventions recorded: Ublituximab, Umbralisib, Bendamustine. Conditions recorded: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma.

Linked to the drug Umbralisib because the registry names it among its interventions and Diffuse large B-cell lymphoma, Follicular lymphoma, Marginal zone lymphoma and Mantle cell lymphoma among its conditions. Registry record only: no result has been read by an editor.